KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
18 hedge funds and large institutions have $54.1M invested in KalVista Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 3 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2.25% less ownership
Funds ownership: 78.14% → 75.89% (-2.3%)
9% less capital invested
Capital invested by funds: $59.2M → $54.1M (-$5.09M)
10% less funds holding
Funds holding: 20 → 18 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$675K |
| 2 |
BlackRock
New York
|
+$6.71K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$4.47K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.47K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$735 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$2.35M |
| 2 |
ARTA
A.R.T. Advisors
New York
|
-$86K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$5.89K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.44K |
| 5 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$29 |
KALV Hedge Fund Activity: Q2 2017 in Review
18 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q2 2017, worth a combined $54.1M — down 8.6% from $59.2M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of KALV and 1 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 4 added.
The largest buyer was Eventide Asset Management, adding an estimated $675K. The largest seller was Vivo Capital, exiting entirely with an estimated $2.35M sold.
- 18 institutional investors held KalVista Pharmaceuticals (KALV) as of Q2 2017, down from 20 in Q1 2017.
- Funds reported $54.1M of KalVista Pharmaceuticals stock for Q2 2017, down 8.6% quarter-over-quarter.
- 1 fund opened new KalVista Pharmaceuticals positions in Q2 2017 and 3 closed out, a net change of -2 holders.
- The largest KalVista Pharmaceuticals buyer in Q2 2017 was Eventide Asset Management, an estimated $675K added.
- The largest KalVista Pharmaceuticals seller in Q2 2017 was Vivo Capital, an estimated $2.35M sold.
Based on aggregated 13F filings for Q2 2017.